Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX102 in neovascular age-related macular degeneration
NCT06196840Phase 2Active, not recruiting
- Sponsor
- Innostellar Biotherapeutics
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LX102 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Innostellar Biotherapeutics. Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity at 36 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
LX102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06196840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196840.